|
|
| Name of Committee | Circulatory System Devices Panel |
| Date and Time | The meeting was held on the following dates:
Jul 28, 04 9:00 AM - 5:00 PM
Jul 29, 04 9:00 AM - 5:00 PM
|
| Location | Holiday Inn, Grand Ballroom
Two Montgomery Village Ave.
Gaithersburg
, MD |
| Contact Information | Geretta Wood, Center for Devices and Radiological Health (HFZ-450), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-443-8320, ext. 143. Information can be found on the FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512625. Please call the Information Line or access this Internet page for up-to-date information on this meeting. |
| Agenda | On July 28, 2004, the committee will discuss, make recommendations, and vote on a premarket approval application supplement for a cardiac resynchronization device. On July 29, 2004, the committee will hear a presentation on Adverse Event Reports for Automatic External Defibrillators from 1996 – 2003. The committee will also discuss and make recommendations on a premarket notification (510(k)) submission for an Over-the-Counter Automated External Defibrillator. Background information for the topics, including the agenda and questions for the committee, will be available to the public one business day before the meeting on the Internet at http://www.fda.gov/cdrh/panelmtg.html. Material for the July 28 session will be posted on July 27, 2004; material for the July 29 session will be posted on July 28, 2004. |
| Procedure | Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by July 14, 2004. On both days, oral presentations from the public will be scheduled for approximately 30 minutes at the beginning of committee deliberations and for approximately 30 minutes near the end of the deliberations. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before July 14, 2004, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation. |
| Conduct | FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at http://www.fda.gov/oc/advisory/ for procedures on public conduct during advisory committee meetings. |
| Related Documents | |
| Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). |
|
